Prognostic significance of serum uric acid in outpatients with chronic heart failure is complex and related to body mass index: Data from the IN-CHF Registry

被引:18
作者
Baldasseroni, S. [2 ]
Urso, R. [1 ]
Maggioni, A. P. [1 ]
Orso, F. [3 ]
Fabbri, G. [1 ]
Marchionni, N. [3 ]
Tavazzi, L. [4 ]
机构
[1] ANMCO Res Ctr, I-50121 Florence, Italy
[2] Azienda Osped Univ Careggi, Sect Internal Med & Cardiol, Dept Heart & Vessel, Florence, Italy
[3] Azienda Osped Univ Careggi, Sect Geriatr Med & Cardiol, Dept Heart & Vessel, Florence, Italy
[4] Maria Cecilia Hosp, Ettore Sansavini Hlth Sci Fdn, GVM Care & Res, Cotignola, Italy
关键词
Uric acid; Heart failure; Prognosis; Body mass index; XANTHINE-OXIDASE; DOUBLE-BLIND; ALLOPURINOL; MORTALITY; CORRELATE; SURVIVAL; MODELS;
D O I
10.1016/j.numecd.2010.08.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and aims: In the field of cardiovascular diseases, elevated levels of serum uric acid (UA) reflect a marked activation of the xanthine oxidase pathway with increase in free radicals production; it is often associated with an inflammatory state, oxygen consumption and endothelial dysfunction. All these associations have been also confirmed in heart failure (HF) but the pathophysiological role of UA in this setting is not well understood. The aim of this study was to evaluate the prognostic role of UA in outpatients enrolled in the Italian Registry of Congestive Heart Failure (IN-CHF). Methods and results: All patients met the European Society of Cardiology (ESC) criteria for diagnosis of HF. We considered patients with complete clinical data and UA level available at the baseline and at 1-year follow-up. The study population was composed of 877 patients aged 63 +/- 12 years. One-year mortality was 10.8% and dead patients had a higher level of UA than survivors (7.1 mg dl (1) vs 6.6 mg dl (1), p < 0.0207). In multivariable full model of analysis, UA did not result in an independent predictor of death in overall population, but only in patients with low body mass index (BMI) (<= 22 kg m(-2)) (hazard ratio (HR): 2.38, 95% confidence interval (CI) 1.36-4.18). In this subgroup, a statistically significant gradual relationship between UA and survival was detected starting from values higher than 8 mg dl (1). Conclusion: Elevated level of UA is not an independent predictor of mortality in chronic HF, but it markedly worsens outcome if associated with low level of BMI. This association is likely an indicator of chronic inflammatory and catabolic state. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:442 / 448
页数:7
相关论文
共 30 条
[1]   Serum uric acid correlates with extracellular superoxide dismutase activity in patients with chronic heart failure [J].
Alcaino, Hernan ;
Greig, Douglas ;
Chiong, Mario ;
Verdejo, Hugo ;
Miranda, Rodrigo ;
Concepcion, Roberto ;
Vukasovic, Jose Luis ;
Diaz-Araya, Guillermo ;
Mellado, Rosemarie ;
Garcia, Lorena ;
Salas, Daniela ;
Gonzalez, Leticia ;
Godoy, Ivan ;
Castro, Pablo ;
Lavandero, Sergio .
EUROPEAN JOURNAL OF HEART FAILURE, 2008, 10 (07) :646-651
[2]   Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study [J].
Anker, SD ;
Negassa, A ;
Coats, AJS ;
Afzal, R ;
Poole-Wilson, PA ;
Cohn, JN ;
Yusuf, S .
LANCET, 2003, 361 (9363) :1077-1083
[3]   Uric acid and survival in chronic heart failure - Validation and application in metabolic, functional, and Hemodynamic staging [J].
Anker, SD ;
Doehner, W ;
Rauchhaus, M ;
Sharma, R ;
Francis, D ;
Knosalla, C ;
Davos, CH ;
Cicoira, M ;
Shamim, W ;
Kemp, M ;
Segal, R ;
Osterziel, KJ ;
Leyva, F ;
Hetzer, R ;
Ponikowski, P ;
Coats, AJS .
CIRCULATION, 2003, 107 (15) :1991-1997
[4]   Relation between serum uric acid and lower limb blood flow in patients with chronic heart failure [J].
Anker, SD ;
Leyva, F ;
PooleWilson, PA ;
Kox, WJ ;
Stevenson, JC ;
Coats, AJS .
HEART, 1997, 78 (01) :39-43
[5]   Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: A report from the Italian Network on Congestive Heart Failure [J].
Baldasseroni, S ;
Opasich, C ;
Gorini, M ;
Lucci, D ;
Marchionni, N ;
Marini, M ;
Campana, C ;
Perini, G ;
Deorsola, A ;
Masotti, G ;
Tavazzi, L ;
Maggioni, AP .
AMERICAN HEART JOURNAL, 2002, 143 (03) :398-405
[6]   Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy [J].
Cappola, TP ;
Kass, DA ;
Nelson, GS ;
Berger, RD ;
Rosas, GO ;
Kobeissi, ZA ;
Marbán, E ;
Hare, JM .
CIRCULATION, 2001, 104 (20) :2407-2411
[7]   Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure -: Results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial [J].
Chung, ES ;
Packer, M ;
Lo, KH ;
Fasanmade, AA ;
Willerson, JT .
CIRCULATION, 2003, 107 (25) :3133-3140
[8]   Enhanced expression and activity of xanthine oxidoreductase in the failing heart [J].
de Jong, JW ;
Schoemaker, RG ;
de Jonge, R ;
Bernocchi, P ;
Keijzer, E ;
Harrison, R ;
Sharma, HS ;
Ceconi, C .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2000, 32 (11) :2083-2089
[9]   Xanthine oxidase inhibition for chronic heart failure: is allopurinol the next therapeutic advance in heart failure? [J].
Doehner, W ;
Anker, SD .
HEART, 2005, 91 (06) :707-709
[10]   Uric acid in cachectic and noncachectic patients with chronic heart failure: Relationship to leg vascular resistance [J].
Doehner, W ;
Rauchhaus, M ;
Florea, VG ;
Sharma, R ;
Bolger, AP ;
Davos, CH ;
Coats, AJS ;
Anker, SD .
AMERICAN HEART JOURNAL, 2001, 141 (05) :792-799